Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in response to this news. The drug-maker’s own target was higher and market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback